

Press Cutting

Citigate
Dewe Rogerson

Publication: WSJ

Date: 10 October 2013

Hutchison MediPharma In Pact with Lilly

HUTCHISON MEDIPHARMA LIMITED, which is majority owned by Hutchison China Meditech Limited (HCM.LN), has entered into a licensing, co-development, and commercialization agreement in China with Eli Lilly and Company (LLY) for Fruquintinib (HMPL-013), an oncology therapy for the potential treatment of various types of solid tumors.

In a separate statement, Hutchison MediPharma said it is also set to receive a milestone payment of \$6 million from Janssen Pharmaceuticals, Inc.

Hutchison China Meditech shares +52.5 pence, or 9.1%, at 632.5 **pence**.